Unichem Laboratories Limited (UNICHEMLAB) AI Stock Analysis

• Market Cap: ₹21.96B
• Dividend Yield: N/A
• Average Volume (3M): 1.03K
• Price to Earnings (P/E): 2.9
• Beta (1Y): 1.08
• Revenue Growth: 25.42%
• EPS Growth: N/A
• Country: IN
• Employees: 2,875
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 37.54
• Shares Outstanding: 70,405,754
• 10 Day Avg. Volume: 1,013
• 30 Day Avg. Volume: 1,033
• PEG Ratio: -0.12
• Price to Book (P/B): 2.00
• Price to Sales (P/S): 2.32
• P/FCF Ratio: -33.98
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: ₹340.00 ▼(-23.26% Downside)
• Action: Reiterated Date: 02/07/26
• Date: Action: Reiterated 02/07/26

The score is led by solid financial fundamentals (growth and a low-leverage balance sheet) but is held back by negative 2025 operating/free cash flow and only modest profitability. Technicals are weak-to-neutral with the stock below key longer-term moving averages, while valuation is supportive due to the low P/E.

Positive Factors

Revenue Growth

Sustained revenue expansion over multiple years signals durable demand across its branded formulations, exports and API segments. Strong top-line growth supports scale, market penetration and provides room to invest in registrations, commercialization and manufacturing capacity long-term.

Improved Gross Margin

A materially higher gross margin points to manufacturing efficiency gains or better product mix, which are structural advantages in pharma manufacturing. Higher gross margins provide operating leverage, helping sustain profitability through price pressure or input-cost cycles over the medium term.

Low Leverage / Strong Equity Base

Low financial leverage and a growing equity base give the company balance-sheet flexibility to fund regulatory filings, geographic expansion and capex without overreliance on debt. This stability supports strategic investments and resilience through industry cycles.

Negative Factors

Negative Operating & Free Cash Flow

Negative operating and free cash flow indicate cash-generation weakness despite revenue growth. This can force reliance on external financing or working capital drawdowns, constraining reinvestment in launches, registrations and capacity and posing liquidity risk over the next several quarters.

Modest Net Profitability

A sub-10% net margin limits retained earnings and internal funding for R&D, regulatory compliance and commercial expansion. Modest profitability leaves less cushion against pricing pressure, input-cost inflation or one-time regulatory costs, weakening long-term earnings resilience.

Margin Volatility / Cash Conversion Inconsistency

Volatile operating margins and inconsistent cash conversion complicate forecasting and capital planning. Structural unpredictability in profitability and cash flows raises execution risk for manufacturing scale-ups, product launches and sustaining regulatory-compliant operations over multiple quarters.

Unichem Laboratories Limited Business Overview & Revenue Model

Company Description

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients, as well as contract manufacturing services. The company was founded in 1944 and is headquartered in Mumbai, India.

How the Company Makes Money

Unichem Laboratories makes money primarily by selling pharmaceutical products, with revenue largely coming from (1) branded formulations sold in India through prescriptions written by physicians and dispensed via pharmacies/hospitals, supported by its field marketing and distribution network; (2) international formulations sold in overseas markets, where earnings depend on product registrations/approvals, commercialization via its own channels and/or local marketing/distribution partners, and ongoing supply of finished dosage forms; and (3) APIs manufactured and sold as intermediate or finished active ingredients to other pharmaceutical companies for use in their formulations. Additional contributors to earnings can include contract manufacturing/third-party manufacturing arrangements, where Unichem produces formulations or APIs for other brand owners, and, where applicable, licensing/technology transfer or milestone/royalty-type income; null if not disclosed in available sources. Overall profitability is influenced by product mix (domestic branded vs. export generics, formulations vs. APIs), regulatory approvals and compliance outcomes, pricing and competitive intensity in each market, and the scale/efficiency of its manufacturing operations.

Unichem Laboratories Limited Financial Statement Overview

Summary

Strong revenue growth and improved gross margin support the score, and the balance sheet is stable with low leverage. Offsetting this, profitability remains modest (net margin 6.51%) and 2025 operating/free cash flow are negative, raising liquidity and cash-conversion concerns.

Income Statement

Unichem Laboratories has demonstrated significant revenue growth, with Total Revenue increasing from $11.56 billion in 2020 to $21.11 billion in 2025, a strong upward trajectory. Gross Profit Margin improved to 59.08% in 2025, highlighting enhanced efficiency. However, the Net Profit Margin remains low at 6.51% in 2025, indicating limited profitability gains. The EBIT and EBITDA margins show volatility, suggesting operational challenges despite recent improvements.

Balance Sheet

The company maintains a healthy balance sheet with Stockholders' Equity rising to $24.51 billion in 2025, demonstrating robust equity support. The Debt-to-Equity Ratio is relatively low at 0.19, indicating low leverage and financial stability. However, the Equity Ratio has slightly decreased, reflecting a minor increase in liabilities relative to assets, warranting cautious monitoring.

Cash Flow

Cash flow performance is mixed, with Operating Cash Flow turning negative in 2025, showing cash management issues. Free Cash Flow remains negative, highlighting potential liquidity challenges. The Operating Cash Flow to Net Income Ratio reflects inconsistency in cash conversion efficiency. Attention is needed to improve cash flow stability and support growth.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	22.26B	21.11B	16.57B	13.25B	12.56B	12.05B
Gross Profit	11.23B	12.47B	3.17B	7.92B	8.07B	7.89B
EBITDA	2.50B	2.65B	742.36M	-456.07M	1.18B	1.41B
Net Income	884.60M	1.38B	-704.74M	-2.02B	330.62M	343.25M
Balance Sheet
Total Assets	35.56B	35.69B	31.69B	31.93B	33.19B	31.26B
Cash, Cash Equivalents and Short-Term Investments	1.94B	895.80M	1.52B	1.89B	3.73B	3.14B
Total Debt	5.02B	4.60B	2.48B	3.14B	3.49B	1.19B
Total Liabilities	11.21B	11.19B	8.07B	7.58B	7.00B	5.69B
Stockholders Equity	24.35B	24.51B	23.62B	24.35B	26.18B	25.57B
Cash Flow
Free Cash Flow	408.30M	-1.44B	-58.53M	-1.29B	-3.87B	-2.55B
Operating Cash Flow	994.40M	-70.20M	166.94M	-850.91M	-2.60B	330.99M
Investing Cash Flow	-375.90M	-2.41B	504.04M	2.03B	1.00B	-735.58M
Financing Cash Flow	259.10M	1.84B	-1.06B	-813.00M	1.91B	-1.21B

Unichem Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 443.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:UNICHEMLAB, the sentiment is Negative. The current price of 443.05 is above the 20-day moving average (MA) of 342.77, above the 50-day MA of 377.87, and below the 200-day MA of 484.74, indicating a bearish trend. The MACD of -18.23 indicates Positive momentum. The RSI at 31.48 is Neutral, neither overbought nor oversold. The STOCH value of 39.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:UNICHEMLAB.

Unichem Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPGLIFE	76 Outperform	₹31.17B	43.39	―	0.85%	―	―
UNICHEMLAB	61 Neutral	₹21.96B	2.94	―	―	25.42%	―
DCAL	58 Neutral	₹26.11B	-74.58	―	―	5.38%	―
AARTIDRUGS	57 Neutral	₹30.89B	23.17	―	0.24%	4.08%	31.52%
GUFICBIO	57 Neutral	₹28.37B	67.80	―	0.03%	7.78%	-34.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%